Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599236 | 0.91 | P2RY12 (0.84) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4098057 | 0.89 | P2RY12 (1.00) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4104695 | 0.87 | P2RY12 (1.00) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4105389 | 0.86 | P2RY12 (0.94) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4105011 | 0.86 | P2RY12 (0.79) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4109623 | 0.86 | P2RY12 (1.00) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4105040 | 0.85 | P2RY12 (0.79) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4115405 | 0.83 | P2RY12 (0.70) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4097854 | 0.83 | P2RY12 (1.00) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4103128 | 0.81 | P2RY12 (0.79) | P2RY12CYP3A4CYP2C9CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | claimed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | claimed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | claimed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP3A4 801/4885CYP2C9 853/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885CYP3A4 324/4885CYP2C9 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.